Japan Moves TRG035 Toward Pediatric Tooth Regrowth Testing
Japan’s most advanced tooth-regrowth program has entered a new regulatory phase, but the distance from notification clearance to clinical use remains substantial. Toregem BioPharma said the Pharmaceuticals and Medical Devices Agency completed its investigation of the clinical trial notification for a Phase IIa study of TRG035, the anti-USAG-1 antibody designed to stimulate tooth development.
The planned study is open-label, non-comparative, and multicentre. It will enroll 24 children with severe congenital tooth agenesis, a population chosen because the drug is intended to address missing teeth caused by genetic developmental failure rather than tooth loss acquired later in life.
One sentence captures the clinical reality: this is still an investigational medicine, not a proven human tooth-regrowth therapy.
TRG035 grew out of a long biological question with obvious restorative-dentistry consequences: whether the human body still retains the developmental machinery to form additional teeth if a growth-inhibiting signal is removed. The drug targets USAG-1, a protein that suppresses tooth development. In preclinical work, blocking that pathway promoted so-called third-generation teeth in mice, ferrets, and dogs, and no notable side effects were reported in those animal studies.
Why USAG-1 Became the Target
The scientific logic is straightforward. Human dentition is normally limited to the primary and permanent sets, but the research program behind TRG035 is built on the idea that vestigial tooth buds may persist and can be coaxed into forming full teeth if inhibitory signaling is suppressed. Katsu Takahashi, who leads the dentistry and oral surgery department at the Medical Research Institute Kitano Hospital in Osaka, has described the concept as a way to move tooth replacement beyond dentures and implants.
By removing a molecular brake on odontogenesis, the treatment is trying to restore a developmental pathway rather than substitute an artificial structure. That distinction matters at the bedside because a natural tooth, if it can be regenerated safely, would preserve periodontal integration, chewing mechanics, and biologic compatibility in ways that implants and prostheses cannot fully replicate.
The appeal is strongest for children with severe congenital hypodontia, defined in this article as the absence of six or more permanent teeth. In that setting, the burden is not simply cosmetic. Missing multiple permanent teeth can complicate mastication, occlusion, speech, and facial development, while repeated prosthetic replacement can become a lifelong maintenance problem.
What the First Human Trial Actually Tested
Human testing began at Kyoto University Hospital in October 2024. The registered Phase I study was designed as a randomised, double-blind, placebo-controlled dose-escalation trial with a target sample of 30 healthy adult men aged 30 to 64 who were missing at least one molar. Its primary aim was safety.
Participants received single intravenous doses of TRG035 or placebo. Secondary outcomes included pharmacokinetics and the development of antibodies against TRG035.
The Japanese clinical trial registry lists the study as complete. Toregem has said Phase I confirmed safety, although detailed results have not been made publicly available. Without those data, the field still lacks a public account of the dose-response relationship, the pharmacokinetic profile, and the immune response monitoring that will be important for any future expansion into broader populations.
A second sentence belongs here because the next step is not cosmetic: the program is now moving from healthy adult volunteers to children with a rare developmental disorder.
The Next Trial Is Smaller, Younger, and More Targeted
The planned Phase IIa study is built around dosing, not efficacy. It will investigate 24 children with severe congenital tooth agenesis across multiple centres, and the design is open-label and non-comparative. Institutional review board assessment is still required, and Toregem has not announced a proposed start date.
That structure reflects an early clinical-development stage in which investigators first need to determine whether the regimen can be delivered safely and plausibly in the intended population. Children with congenital absence of teeth are a very different cohort from healthy adults missing a molar, especially when tooth-development pathways may still be active during childhood. The trial’s small size also makes the study better suited to identifying dosing signals than to establishing whether clinically meaningful tooth regrowth will actually occur.
The company’s August 2026 announcement should be read in that context. Completion of the PMDA’s investigation of the clinical trial notification does not amount to regulatory approval of the drug. It simply clears one procedural hurdle before site-level ethics review and eventual enrollment, if all remaining requirements are satisfied.
A Broader Regenerative Dentistry Pipeline Is Still Fragmented
TRG035 is only one track in a much wider effort to regenerate oral tissues. Other strategies include stem cells, bioengineered tooth structures, and mineral repair of damaged enamel, but these approaches sit at very different stages of development.
Stem cell research has produced encouraging laboratory findings, including organoids capable of secreting proteins involved in enamel formation and studies suggesting that cell location influences how tooth structures organize during growth. Bioengineering work has also shown that hybrid human and porcine cell constructs can develop dentin and cementum in a scaffold implanted in a miniature pig’s jaw. Even so, each of these lines of research remains separated from routine clinical dentistry by major questions of safety, durability, manufacturing, cost, and regulation.
The ethical and economic issues around stem-cell based regeneration are especially unresolved. Concerns about embryonic cell sources, immune rejection, and access cost remain central, even where autologous cells may reduce those barriers. None of those uncertainties disappear simply because the biological signal looks promising in a lab model.
What Would Have to Happen Before Patients See It
Toregem has said it hopes the medicine could be ready for general use in 2030, but that timeline is provisional. Before anything like routine availability can be considered, TRG035 would still need Phase II efficacy data, further regulatory review, and eventual approval.
The current development path is also narrow in its intended indication. The next study is focused on severe congenital hypodontia, not on acquired adult tooth loss from periodontal disease, trauma, or decay. Toregem has said it also envisions treatments for acquired tooth loss, but that remains a future goal rather than a clinical reality.
For now, the field has reached an important threshold without crossing into treatment availability. The drug has passed through early human safety testing and has been cleared for the next regulatory step toward pediatric dosing evaluation in Japan. What remains unknown is whether suppressing USAG-1 can reliably produce a functioning human tooth in the right patient at the right developmental stage, with a safety profile suitable for children who may need more than a single regenerated tooth over a lifetime.